The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Researchers from Virginia Commonwealth University confirm that shortened treatment times negatively impact cure rates for Hepatitis C genotype 2 or 3. These new study results warn us that treatments shortened to three or four months have higher relapse rates than the average six-month interval for these genotypes.
Continue reading »Biotech company IQur's new blood test for evaluating liver fibrosis has been approved in the UK. The 'Enhanced Liver Fibrosis Test' detects and monitors liver damage without the need for an invasive liver biopsy.
Continue reading »Humans have a potent chemical within every cell for protection against dangerous substances. Learn why one particular antioxidant is considered the be the body's most important, and what makes it so vital to the health of your liver.
Continue reading »By combining standard liver blood tests with a patient’s age, French researchers have developed a reliable and inexpensive method to determine the extent of liver fibrosis in people with Hepatitis C. While the accuracy of this calculation is only valid within a narrow window of liver injury, it may save many patients from undergoing costly and invasive liver biopsies.
Continue reading »According to the Department of Health and Mental Hygiene, it was recently discovered that a NYC anesthesiologist might have transmitted Hepatitis C to at least three patients. With over 4,500 other people treated by this same doctor being made aware of their potential risk of exposure, find out how common transmission of the disease is within a medical setting.
Continue reading »A 2006 report demonstrated the benefits of marijuana for people undergoing interferon and/or ribavirin treatment for Hepatitis C. On the other hand, recent studies have shown the use of marijuana may increase the acceleration of the disease process and possibly cause decreased immune function. The information presented in this article is not intended to encourage or discourage illegal activity, but rather to provide the reader with proven facts about marijuana's impact on the liver.
Continue reading »Now in Phase II clinical trials, a new, oral HCV protease inhibitor, SCH 503034, may defeat the virus in interferon non-responders. Find out how well the drug is tolerated and how it is able to reduce the viral load of non-responders with genotype 1.
Continue reading »Healthcare workers confirm that the Hepatitis C virus does not discriminate and lurks everywhere. While it is only transferred through blood, two nurses from Massachusetts review the many possible routes of Hepatitis C transmission and admit that most people have no idea they are infected.
Continue reading »Here is an example of an article on the recent claims of a Hepatitis C "cure." Readers should take note that the study included those who have already beaten the virus with interferon combination therapy (ICT). The good news is that once you beat the virus with ICT, you are likely to remain virus-free. The bad news is that ICT only helps approximately one quarter of those infected with the most common strain of the virus, when you take into account those who had to stop or adjust their treatment due to the severe side effects.
Continue reading »Read about one columnist's personal experience with Hepatitis C and discover why, regardless of how someone is infected, early detection and treatment offer the greatest hope for surviving the disease.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
